Chemomab Therapeutics Ltd. Announces Effectiveness of Form S-4 Registration Statement for Proposed Merger with Scipher Medicine Corporation

Chemomab Therapeutics said the SEC declared effective Snowdrift Parent Corporation’s Form S-4 registration statement on October 30, 2026. The effectiveness follows a previously disclosed Agreement and Plan of Merger; the provided article text does not state that the merger has closed or provide transaction terms.